LENZ Therapeutics Q4 2025 Earnings Call Summary: Strategic Execution and Market Dynamics

LENZ Therapeutics reported Q4 2025 earnings, attributing early success to real-world clinical performance matching trial data. The company is focusing on strategic execution and market dynamics, prioritizing a 'ample-first' approach to drive natural self-selection and targeting a broad population of 128 million Americans. The sales force expansion to 117 reps is expected to increase call frequency and reach approximately 15,000 ECPs, with financial guidance assuming a steady gross-to-net ratio of approximately 90%. The international strategy targets over 10 global regulatory submissions by the end of 2026. Q4 2025 net product revenues reached $1.6 million, with over 20,000 monthly paid and filled prescriptions. SG&A expenses increased 43% sequentially to $39.6 million, primarily driven by the establishment of the sales force and non-recurring investments.